S Reducion of infarction size as a target Mohamed Mahmoud Abd El Ghany Mohamed Mahmoud Abd El Ghany Cardiology Professor of Cairo University.

Slides:



Advertisements
Similar presentations
Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study Presented at American College of Cardiology Scientific.
Advertisements

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Post-conditioning the human heart to reduce infarct size
Postconditioning: A new link in nature’s armor against myocardial ischemia/reperfusion injury Gao Qin
Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.
Can we prevent stent restenosis after coronary stent implantation
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
Improving survival in symptomatic ischemic patients with left ventricular dysfunction Beneficial effects of long-term trimetazidine* therapy Fragasso G.
Ischemic heart disease
Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction Keshava Rajagopal,
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
EMS 353. Lectures 6 Dr. Maha Khalid physiology of pharmacology cardiovascular system.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
1 DIAGNOSTICS OF Acute Coronary Syndromes At the end of this self study the participant will: Verbalize meanings of specific ECG changes: –ST Elevation.
Ischemic heart disease Basic Science 3/15/06. All of the following concerning coronary artery anatomy are correct except: The left main coronary artery.
Myocardial preconditioning Joel Starkopf Departement of Anaesthesiology and Intensive Care University of Tartu Estonia.
Yan Wu, Xiangru Lu, Fuli Xiang, and Qingping Feng
Differential regulation of calcium regulatory proteins between sevoflurane postconditioning and delayed remote ischemic preconditioning in an isolated.
Remote Ischemic Conditioning: An Update on Mechanisms Remote Ischemic Conditioning: An Update on Mechanisms Karin Przyklenk PhD Director, Cardiovascular.
Silent Ischemia STABLE CAD
Minimise the damage – Pre- and Post-conditioning Dr Derek J Hausenloy The Hatter Cardiovascular Institute, University College London, UK. Myocardial Recovery.
Angiographic Estimates of Myocardium at Risk During Acute Myocardial Infarction: a Validation Study Using Cardiac MRI José T. Ortiz, Sheridan N. Meyers,
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
The index of microvascular resistance measured acutely predicts infarct severity and left ventricular function at 3 months in patients with ST segment.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
Ischemic Conditioning and Endothelial Function Todd Anderson Libin Cardiovascular Institute University of Calgary.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
TAHAR EL KANDOUSSI, SARA ECHERKI, NAWAL DOGHMI, MOHAMED CHERTI. SEcurite de l’Echocardiographie de stress : plutôt l’effort. Cardiology B Department, Ibn.
Myocardial Infarction Angina Pectoris What is an MI?
Long Term Benefit Of Early Pre-reperfusion Metoprolol Administration In Patients With Acute Myocardial Infarction: Results From The METOCARD-CNIC trial.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Different Effects of a High-Cholesterol Diet on Ischemic.
Date of download: 6/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiomyocyte-Specific Deletion of Gsk3α Mitigates.
Gender differences in AMPK activation in the heart and white quadriceps muscle following exercise training in mice. Matthew Peterson Supervisor: Dr. Paul.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prediction of Cardiac Events in Patients With Reduced.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Total Occlusion Study of Canada (TOSCA-2) Trial
Improving Outcomes in Cardiogenic Shock
Revascularization in Patients With Left Ventricular Dysfunction:
Management of ST-Elevation Myocardial Infarction
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
The pathophysiology of myocardial infarction-induced heart failure
Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L
Modified Rankin score 0-2
Time Is Myocardium and the Wavefront of Necrosis
American College of Cardiology Presented by Dr. Michel R. Le May
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
ß-blocker therapy for heart failure at the turn of the millennium
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
Constantijn Franssen et al. JCHF 2016;4:
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

s Reducion of infarction size as a target Mohamed Mahmoud Abd El Ghany Mohamed Mahmoud Abd El Ghany Cardiology Professor of Cairo University

s  The size of the infarction is a major determinant of both the risk of death and the likelihood of subsequent heart failure

s initial perfusion defect - final infarct size Salvage index = initial perfusion defect J Nucl Med 2004; 45:725–729 Conclusion:  This study clearly demonstrated that salvage index predicts mortality in patients with acute myocardial infarction after reperfusion therapy

s Research during the past two decades has tried to elucidate the critical steps in the injury and subsequent killing of myocardial cells, with the hope that antagonizing these steps may provide new cardioprotective therapies

s  Ischemic preconditioning  Preischemic Selenium Status  Myocardial reperfusion - Time to reperfusion - Method of reperfusion - BP  Myocardial O2 consumption  Connexin 43  C reactive protein Determinants of Myocardial Infarct Size

s Ischemic preconditioning Enhancement of myocardial tolerance against infarction induced by a brief sublethal episodes of ischemia

s First window of preconditioning Second window of preconditioning

Reduction of infarct size and post-ischemic inflammation from a highly selective adenosine A2A receptor agonist, ATL-146e, in reperfused canine myocardium Am J Physiol Heart Circ Physiol (December 9, 2004) In canine models of myocardial infarction, low dose, intravenous administration of the highly selective adenosine A2A receptor agonist, ATL-146e, significantly reduced infarct size, both as a pretreatment and when administered just prior to reperfusion,

s  Ischemic preconditioning  Preischemic Selenium Status  Myocardial reperfusion - Time to reperfusion - Method of reperfusion - BP  Myocardial O2 consumption  Connexin 43  C reactive protein Determinants of Myocardial Infarct Size

s Antioxidants & Redox Signaling 2004, 6(4): High selenium Diet Low selenium Diet 10 W Coronary occlusion Coronary occlusion Infarct size ±1.19 % Infarct size ±4.14 % Conclusion:  Preischemic body selenium status is a major determinant of the outcome of myocardial ischemia in vivo in rats probably because it influences the cellular antioxidant activity.

s  Ischemic preconditioning  Preischemic Selenium Status  Myocardial reperfusion - Time to reperfusion - Method of reperfusion - BP  Myocardial O2 consumption  Connexin 43  C reactive protein Determinants of Myocardial Infarct Size

s Heart 2000;84:142–148 Conclusion: In this single large trial, the beneficial effect of time to thrombolysis on infarct size and ejection fraction was restricted to treatment given within two hours of symptom onset,

s J Nucl Med 2004; 45:725–729 Conclusion: Mechanical reperfusion is associated with higher value of myocardial salvage compared to thrombolytic

Eur Heart J, 2002: 23: 1112–1117 Distal embolizationP value No (n=167)Yes (n=27) Patency151 (92%)19 (73%)0.009 LVEF (%)51±942± Mortality (5 years) 15 (9%)12 (44%)<0.001 Death or recurrent MI (5 years) 24 (14%)14 (52%)<0.001

s J Am Coll Cardiol 2009 :53 ; Slow flow/no reflow(%) v

s J Am Coll Cardiol 2009 :53 ; MVO IS Conclusion: Manual aspiration thrombectomy preserves microvascular Integrity and reduces final IS after STEMI; thus, it may represent a useful adjunct to pharmacotherapy

s Inadvertent drop in systemic BP Elevated systemic BP and resultant LVH Equally detrimental on the infarct size and exerts a deleterious effect on the progression of myocardial necrosis

s  Ischemic preconditioning  Preischemic Selenium Status  Myocardial reperfusion - Time to reperfusion - Method of reperfusion - BP  Myocardial O2 consumption  Connexin 43  C reactive protein Determinants of Myocardial Infarct Size

s MVO2 Inotropic Status Wall Stress Heart Rate Radius Pressure Wall stress = 2 Thickness Beta blockers Nitroglycerine

Esmolol and Cardiopulmonary Bypass During Reperfusion Reduce Myocardial Infarct Size in Dogs DeBakey Institute, Texas A&M University, College Station, Texas B - Blockade may be cardioprotective during reperfusion through various mechanisms and may enhance myocardial salvage, even when treatment is initiated as late as with the onset of reperfusion. (Ann Thorac Surg 2001;72:1964 –9)

s  Ischemic preconditioning  Preischemic Selenium Status  Myocardial reperfusion - Time to reperfusion - Method of reperfusion - BP  Myocardial O2 consumption  Connexin 43  C reactive protein Determinants of Myocardial Infarct Size

s *p J Am Coll Cardiol 2003;41:681– 6 In humans, Reduced Cx43 expression ( Electrical uncoupling) induced by acute ischemia enhances arrhythmogenesis, but it may also protect the heart by limiting intercellular spread of chemical mediators of injury Conclusion:  Cx43-deficient mice develop smaller infarcts than wild-type mice following coronary ligation  New therapies designed to decrease the risk of arrhythmias by enhancing intercellular communication could lead to larger infarcts caused by persistent coronary occlusion

s  Ischemic preconditioning  Preischemic Selenium Status  Myocardial reperfusion - Time to reperfusion - Method of reperfusion - BP  Myocardial O2 consumption  Connexin 43  C reactive protein Determinants of Myocardial Infarct Size

s Richard et al. NEJM 2006 :355;5

s  CRP levels increase dramatically in patients with myocardial infarction beginning 6 hours after the onset of ischemia and peaking at approximately 50 hours  CRP values after acute myocardial infarction predict outcome, including death and heart failure  Pepys et al. designed a small molecule, 1,6- bis(phosphocholine)-hexane ( Bis(PC)-H), that binds CRP and prevents interactions between CRP and its various ligands, as well as CRP-induced complement activation (Suleiman M et al. J Am Coll Cardiol 2006;47:962-8) (Pepys et al,Nature 2006;440: )

s Richard et al. NEJM 2006 :355;5

s  Reduction of infarct size is very important  The size of the infarction is a major determinant of both the risk of death and the likelihood of subsequent heart failure  Measures for infarct size reduction should start before occurance of event

Thank you